2 -Macroglobulin,   1 -antitrypsin, and antithrombin III in plasma and serum during fibrinolytic therapy with urokinase.
D000284:Administration, Oral; D000510:Alpha-Globulins; D000933:Antifibrinolytic Agents; D000991:Antithrombins; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005947:Glucose / Q000008:administration & dosage; D006801:Humans; D007275:Injections, Intravenous; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy; D010770:Phosphotransferases / Q000037:antagonists & inhibitors; D013997:Time Factors; D014361:Trypsin Inhibitors / Q000097:blood*; D014859:Warfarin / Q000008:administration & dosage
D000510:Alpha-Globulins; D000933:Antifibrinolytic Agents; D000991:Antithrombins; D005343:Fibrinolytic Agents; D014361:Trypsin Inhibitors; D014859:Warfarin; D010770:Phosphotransferases; D005947:Glucose